Company will develop a cell-based assay for discovery projects and carry out compound management.
Galapagos entered into a €41. million, or $5.4 million, drug discovery and compound-management agreement with Dart Neuroscience (DNS).
Galapagos service division, BioFocus DPI, will develop a cell-based assay for DNS’ drug discovery programs for brain disorders. It will perform high-throughput screening and hit expansion using BioFocus DPI’s compound collections. The three-year contract also calls for certain compound-management projects.
“This collaboration maximizes several key BioFocus DPI strengths: assay development and high-throughput screening as well as compound libraries and compound management,” points out Onno van de Stolpe, CEO of Galapagos.
